Today: 7 February 2026
Subscribe
Browse Category

Healthcare Industry News 14 December 2025 - 23 December 2025

UnitedHealth (UNH) Stock News Today (Dec. 23, 2025): Audits, Washington Policy Pressure, and Analyst Price Targets

UnitedHealth (UNH) Stock News Today (Dec. 23, 2025): Audits, Washington Policy Pressure, and Analyst Price Targets

UnitedHealth Group Incorporated (NYSE: UNH) traded nearly flat on Tuesday, Dec. 23, as investors weighed a fresh wave of operational reform commitments against an increasingly political U.S. health-insurance backdrop heading into 2026. UNH was last indicated around $325 in mid-session trading, after opening near $324 and moving between roughly $324–$328. The calm tape belies why the stock has been a lightning rod into year-end: external reviews of key business practices, Justice Department scrutiny tied to Medicare Advantage billing, and headlines out of Washington that could reshape pricing expectations for the entire insurer group. Reuters+1 UNH stock price today: A quiet
23 December 2025
····
Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences, Inc. (NASDAQ: GILD) opened the holiday-shortened week with a mix of pipeline expansion and policy-driven uncertainty—two themes that can quickly move large-cap biopharma stocks even when overall market volume is lighter than usual. On Monday, December 22, 2025, Gilead announced it has exercised its option to license Assembly Biosciences’ investigational herpes simplex virus (HSV) programs—a move that strengthens Gilead’s long-term antiviral pipeline beyond HIV. The development lands just days after Gilead joined other major drugmakers in a Trump administration “most-favored-nation” drug-pricing agreement tied to tariff relief and direct-to-consumer drug access via TrumpRx.gov. Gilead+2Gilead+2 As of the latest available
22 December 2025
·····
Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025

Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025

Amgen Inc. (NASDAQ: AMGN) is back in the spotlight on Monday, December 22, 2025, as investors weigh a wave of White House drug‑pricing agreements, a fast‑moving “most‑favored‑nation” (MFN) pricing push, and what it could all mean for Amgen’s earnings power in 2026. The stock traded higher in Monday’s session, with market data showing shares around $331. While the headlines are centered on drug prices, the market’s reaction has been notably measured: several analyst notes published today suggest these deals may be designed to reduce political and tariff uncertainty more than they materially compress pharma profits—at least in the near term.
22 December 2025
·····
Johnson & Johnson Stock (JNJ) News Today: Latest Updates, Analyst Forecasts, and What Could Move Shares Next (Dec. 22, 2025)

Johnson & Johnson Stock (JNJ) News Today: Latest Updates, Analyst Forecasts, and What Could Move Shares Next (Dec. 22, 2025)

December 22, 2025 — Johnson & Johnson (NYSE: JNJ) ends the year with momentum on its side, but not without familiar crosswinds. After a strong 2025 run, investors are balancing a string of late-year regulatory wins and product catalysts against ongoing talc-related litigation headlines—two forces that continue to shape near-term sentiment around Johnson & Johnson stock. As of Monday’s latest available pricing, JNJ shares traded around $206.63. JNJ stock snapshot: strong 2025 rally, but the market is reassessing “what’s next” Johnson & Johnson has been treated like a “defensive growth” name in 2025—an unusual combination that typically requires two things:
22 December 2025
·····
AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

December 21, 2025 — AbbVie Inc. (NYSE: ABBV) heads into the final stretch of 2025 near multi‑month highs, but the weekend news cycle (starting December 20, 2025) has put a familiar theme back in the spotlight: U.S. drug pricing policy. At the same time, Wall Street’s newest notes show a market still split between strong fundamentals (Skyrizi/Rinvoq momentum and a dividend raise) and policy/pipeline debates that could shape sentiment into 2026. ABBV last traded around $226.82 after Friday’s session, up about 1.8% on the day, and sitting within striking distance of its 52‑week high. MarketWatch Where AbbVie stock stands as
21 December 2025
·····
Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

Johnson & Johnson Stock JNJ: Talc Verdict, Drug Pricing Pressure, and the 2026 Forecast as of Dec. 20, 2025

Dec. 20, 2025 — Johnson & Johnson (NYSE: JNJ) is closing out the week with investors weighing a fresh talc-related jury verdict, a fast-moving U.S. drug-pricing policy push that could soon reach J&J, and a stream of late-2025 catalysts spanning FDA-related updates, M&A, and a major MedTech restructuring plan. JNJ shares last traded around $206.37, down about 0.9% from the prior close, after touching higher levels earlier in the week. The bigger picture: J&J has delivered a strong 2025 run by large-cap healthcare standards, with total return measures showing roughly high‑40% year-to-date performance by mid-to-late December. Finance Charts Johnson &
20 December 2025
·····
Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Dec. 20, 2025 — Eli Lilly and Company (NYSE: LLY) is closing out 2025 with momentum—and with fresh headlines that underscore why Eli Lilly stock has become one of the market’s most closely watched healthcare names. Shares last closed at $1,071.44 (Dec. 19) after trading between $1,059.01 and $1,075.38, keeping the stock within reach of its recent highs. Stock Analysis The bigger story isn’t just the price. Lilly entered the rarefied “$1 trillion market value” club this year—an inflection point for a pharmaceutical company—and it’s doing so on the back of a rapidly expanding obesity and cardiometabolic franchise, a pipeline
20 December 2025
·····
Gujarat Kidney and Super Speciality IPO: Price Band Set at ₹108–₹114 for ₹251 Crore Issue; Key Dates, GMP Status, and Expansion Roadmap

Gujarat Kidney and Super Speciality IPO: Price Band Set at ₹108–₹114 for ₹251 Crore Issue; Key Dates, GMP Status, and Expansion Roadmap

Updated: December 18, 2025 — Gujarat Kidney and Super Speciality Ltd has finalised the price band for its upcoming mainboard IPO, setting the stage for a ₹251 crore public issue that will open next week. The offer is entirely a fresh issue—meaning the company (not selling shareholders) will receive the proceeds—at a time when investors are tracking healthcare listings closely for both growth visibility and execution risks. The Economic Times+1 Gujarat Kidney and Super Speciality IPO: price band, dates, and key application details The company has fixed the IPO price band at ₹108–₹114 per equity share. The public issue is
18 December 2025
···
Medline IPO: MDLN Debuts on Nasdaq After $6.26 Billion Raise in 2025’s Biggest Global Listing

Medline IPO: MDLN Debuts on Nasdaq After $6.26 Billion Raise in 2025’s Biggest Global Listing

Medline is officially back in the public markets. On Wednesday, December 17, 2025, the Northfield, Illinois-based medical supply powerhouse begins trading on the Nasdaq Global Select Market under the ticker MDLN, following an upsized initial public offering that raised about $6.26 billion—the largest global IPO of 2025. Reuters+2Medline Newsroom+2 For Wall Street, the scale of the deal matters. For hospitals and health systems, the company’s name is already familiar: Medline sits deep inside the day-to-day plumbing of healthcare, supplying everything from surgical kits and gloves to protective apparel and logistics services. The IPO is also a major moment for the
17 December 2025
·····
Danaher Stock (DHR) News Today: BofA Lifts Price Target to $265, Wells Fargo to $240 as 2026 Normalization Comes Into Focus

Danaher Stock (DHR) News Today: BofA Lifts Price Target to $265, Wells Fargo to $240 as 2026 Normalization Comes Into Focus

Danaher Corporation (NYSE: DHR) is back in the spotlight on Monday, December 15, 2025, after two fresh Wall Street updates pushed Danaher stock back into the “what’s next” conversation for life-science and diagnostics investors. In afternoon trading, DHR hovered around $227 per share, modestly higher on the day. The bigger story isn’t a dramatic price move—it’s the shift in tone among analysts: multiple firms are positioning 2026 as a potential “normalization year” for demand trends across life sciences tools and diagnostics, with Danaher seen as one of the large-cap bellwethers. Below is a full, publication-ready breakdown of today’s news, forecasts,
15 December 2025
·····
UnitedHealth Group (UNH) Stock News and Forecasts on Dec. 14, 2025: DOJ-Amedisys Deal, Optum Opioid Lawsuit, Earnings Date, and Analyst Targets

UnitedHealth Group (UNH) Stock News and Forecasts on Dec. 14, 2025: DOJ-Amedisys Deal, Optum Opioid Lawsuit, Earnings Date, and Analyst Targets

Updated: December 14, 2025 UnitedHealth Group Incorporated (NYSE: UNH) is ending the weekend with a rare combination for a Dow heavyweight: a near-term relief catalyst (a key court-approved DOJ settlement tied to the Amedisys deal) alongside fresh legal headline risk (West Virginia’s opioid-related lawsuit targeting Optum). Add an upcoming full-year 2025 earnings release with 2026 guidance in late January, and UNH stock enters the final stretch of 2025 as one of the market’s most closely watched healthcare bellwethers. Department of Justice+2Reuters+2 Below is the full roundup of the most current news, forecasts, and analyst commentary available as of 14.12.2025, plus
14 December 2025
·····
Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Updated: December 14, 2025 (Sunday) Novo Nordisk A/S shares ended this week with a rebound after a choppy start, as investors weighed three heavyweight catalysts: (1) the EU regulator’s support for a higher-dose Wegovy, (2) the long-telegraphed India launch of Ozempic at a sharply lower price point, and (3) the closing of Novo’s multibillion-dollar acquisition of Akero Therapeutics to expand beyond obesity/diabetes into MASH (fatty liver disease). Reuters+2Reuters+2 While the broader 2025 narrative has been painful—Novo’s U.S. ADR is down roughly ~41% YTD by some market-data services, and Danish-listed shares have been down more than 50% at points this year—the
14 December 2025
·······
1 … 6 7 8 9 10 … 12

Stock Market Today

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

7 February 2026
Walmart shares rose 3.3% Friday to $131.18, up 10% since Jan. 30, as the Dow closed above 50,000 for the first time. The retailer’s market value crossed $1 trillion this week. Investors await January inflation data on Feb. 13 and Walmart’s quarterly results on Feb. 19 for signs of continued momentum.
Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

7 February 2026
Caterpillar shares surged 7.1% to $726.20 Friday, driving the Dow above 50,000 for the first time. The move erased recent losses and followed insider selling by Group President Bob De Lange earlier in the week. Deere and CNH Industrial also gained as investors rotated into industrial stocks. Markets await next week’s U.S. jobs and inflation data.
Go toTop